Skip to content
Search

Latest Stories

No immediate proof to support whistleblower complaints: Infosys

INDIAN IT giant Infosys on Monday (4) said that it hasn’t obtained any evidence to prove the allegations in a whistleblower letter received last month.

The complaints are still under probe, and the company is not in a position to determine “concreteness, credibility and materiality of complaints,” Infosys said.


According to reports, the complaint by a group that calls itself "ethical employees" had alleged chief executive officer Salil Parekh and chief financial officer Nilanjan Roy were indulging in "unethical practices" to boost short-term revenue and profits.

The US Securities and Exchange Commission (SEC) began a probe into the claims, and its Indian counterpart, the Securities and Exchange Board of India (SEBI), asked the company to submit information on the complaints.

In a communication to India’s National Stock Exchange (NSE), Infosys said: “With respect to the anonymous complaints, there is no prima facie evidence that the company has received until date to corroborate any of the allegations made.”

Since the allegations were not deemed material, the company was not obligated to disclose them, Infosys said in response to the NSE’s query why it had not disclosed the anonymous letter it received.

The Bengaluru-based company’s chairman, Nandan Nilekani, said earlier that Parekh and Roy, who was also accused of wrongdoing in the letter, were recused from the board’s probe.

Former chief executive Vishal Sikka quit the company after a whistleblower complaint.

The committee began consultation with independent internal auditors EY and has retained law firm Shardul Amarchand Mangaldas & Co to conduct an independent investigation, Nilekani noted in his statement to the stock exchanges earlier.

Infosys last month had said the whistleblower's complaint has been placed before the audit committee as per the company's practice and that it would be dealt with according to the company’s policy.

More For You

modi-trump-getty
Trump shakes hands with Modi during a joint press conference at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)

Key issues in India, US trade talks

TRADE talks between India and the US have hit a roadblock over disagreements on duties for auto components, steel and farm goods, Indian government sources said to Reuters, dashing hopes of reaching an interim deal ahead of president Donald Trump's July 9 deadline to impose reciprocal tariffs.

Here are the key issues at play:

Keep ReadingShow less
Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less